Literature DB >> 24425349

Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.

William O Osburn1, Anna E Snider, Brittany L Wells, Rachel Latanich, Justin R Bailey, David L Thomas, Andrea L Cox, Stuart C Ray.   

Abstract

UNLABELLED: The contribution of humoral immune responses to spontaneous control of hepatitis C virus (HCV) infection remains unclear. We assessed neutralizing antibody (nAb) responses during acute HCV infection to determine whether infection outcome is associated with the nAb response, specifically, its timing or breadth (neutralization of multiple genotype-matched variants). A representative genotype 1 HCV pseudoparticle (HCVpp) library, consisting of 19 genetically distinct genotype 1 HCVpp that comprise the natural variability of genotype 1 E1E2 sequences, was used to assess anti-genotype 1 nAb responses during acute infection in at-risk persons followed prospectively. Neutralization of individual library HCVpp by the last viremic plasma sample obtained before clearance was compared to either 1-year post-initial viremia or clearance time-matched specimens obtained from subjects developing persistent infection. In persistently infected persons nAb responses were delayed then progressively broadened, whereas in persons who controlled viremia broader responses were detected early and contracted after clearance of viremia. Surprisingly, the breadth of anti-genotype 1 nAb responses was not dependent on subjects' infection genotype. Also, individual library HCVpp neutralization sensitivity was not associated with any known E2 sequence determinants. Interestingly, two single nucleotide polymorphisms in the HLA-DQ locus were associated with nAb breadth.
CONCLUSION: Control of HCV infection is associated with more rapid development of a broad nAb response, independent of the infection viral genotype, providing further evidence for the role of nAb in controlling HCV infection and the potential benefit of generating broad anti-HCV nAb responses by vaccination.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24425349      PMCID: PMC4043926          DOI: 10.1002/hep.27013

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

1.  The epidemic behavior of the hepatitis C virus.

Authors:  O G Pybus; M A Charleston; S Gupta; A Rambaut; E C Holmes; P H Harvey
Journal:  Science       Date:  2001-06-22       Impact factor: 47.728

2.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Authors:  Daniel Steinmann; Heidi Barth; Bettina Gissler; Peter Schürmann; Mohammed I Adah; J Tilman Gerlach; Gerd R Pape; Erik Depla; Dirk Jacobs; Geert Maertens; Arvind H Patel; Geneviève Inchauspé; T Jake Liang; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Authors:  Kimberly A Dowd; Dale M Netski; Xiao-Hong Wang; Andrea L Cox; Stuart C Ray
Journal:  Gastroenterology       Date:  2009-03-17       Impact factor: 22.682

5.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

Review 6.  Neutralizing antibody response to hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Steven K H Foung
Journal:  Viruses       Date:  2011-11-02       Impact factor: 5.048

7.  Genome-wide analysis of haplotype interaction for the data from the North American Rheumatoid Arthritis Consortium.

Authors:  Jungsun Park; Junghyun Namkung; Mina Jhun; Taesung Park
Journal:  BMC Proc       Date:  2009-12-15

Review 8.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

9.  Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.

Authors:  Priya Duggal; Chloe L Thio; Genevieve L Wojcik; James J Goedert; Alessandra Mangia; Rachel Latanich; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Marion G Peters; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Leslie H Tobler; Michael P Busch; Graeme Alexander; Hugo R Rosen; Xiaojiang Gao; Mohamed Abdel-Hamid; Richard Apps; Mary Carrington; David L Thomas
Journal:  Ann Intern Med       Date:  2013-02-19       Impact factor: 25.391

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  129 in total

1.  Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Authors:  Jannick Prentoe; Rodrigo Velázquez-Moctezuma; Steven K H Foung; Mansun Law; Jens Bukh
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

Review 2.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

Review 3.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

4.  HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Authors:  Andrew I Flyak; Stormy Ruiz; Michelle D Colbert; Tiffany Luong; James E Crowe; Justin R Bailey; Pamela J Bjorkman
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

5.  Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Authors:  Valerie J Kinchen; Muhammad N Zahid; Andrew I Flyak; Mary G Soliman; Gerald H Learn; Shuyi Wang; Edgar Davidson; Benjamin J Doranz; Stuart C Ray; Andrea L Cox; James E Crowe; Pamela J Bjorkman; George M Shaw; Justin R Bailey
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

6.  Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Authors:  Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Infect Genet Evol       Date:  2017-01-05       Impact factor: 3.342

7.  CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Authors:  Justin R Bailey; Kimberly A Dowd; Anna E Snider; William O Osburn; Shruti H Mehta; Gregory D Kirk; David L Thomas; Stuart C Ray
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

8.  Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Authors:  Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman
Journal:  Virology       Date:  2017-11-10       Impact factor: 3.616

9.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

10.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.